Market Place
Sourcing Support
Teva Gains Biosimilar Momentum with Approval of Ponlimsi &Xolair
30 Mar 2026 //
GLOBENEWSWIRE
Biolojic Earns Teva Milestone for First AI Multibody TEV `325
25 Mar 2026 //
GLOBENEWSWIRE
Skyhawk, Santhera Name New CCO`s To Steer Commercial Paths
11 Mar 2026 //
FIERCE PHARMA
Teva`s $400M Blackstone deal to fund Sanofi-partnered IBD drugTev
05 Mar 2026 //
GLOBENEWSWIRE
Sanofi points to long-term efficacy of Teva-partnered IBD drug
17 Feb 2026 //
PRESS RELEASE
AJOVY Reduces Episodic Migraine Days in SPACE Trial
14 Jan 2026 //
GLOBENEWSWIRE
Alvotech, Teva Set U.S. Date For AVT06, Biosimilar To Eylea
19 Dec 2025 //
GLOBENEWSWIRE
Teva Gets EU Nod for Ponlimsi and Degevma Biosimilars
27 Nov 2025 //
PHARMIWEB
Teva Gets Eu Nod for Ponlimsi and Degevma Biosimilars
26 Nov 2025 //
PHARMIWEB
Teva Gets EU Nod for Ponlimsi & Degevma Biosimilars
26 Nov 2025 //
GLOBENEWSWIRE
Teva Launches Rise to Speed for AI and Biotech Breakthroughs
19 Nov 2025 //
GLOBENEWSWIRE
Teva, Prestige Bio Sign Deal For Tuznue® Commercialization
20 Oct 2025 //
GLOBENEWSWIRE
MedImpact offers low-cost ustekinumab-aekn biosimilar to US
18 Aug 2025 //
BUSINESSWIRE
Teva’s PEARL Study: AJOVY® Effective for Chronic Migraine
23 Jun 2025 //
GLOBENEWSWIRE
Teva, Biolojic Begin IND Studies for BD9 in Asthma, Dermatitis
27 May 2025 //
GLOBENEWSWIRE
Teva`s Celiac Disease Candidate Gets FDA Fast Track Designation
27 May 2025 //
GLOBENEWSWIRE
Teva & Alvotech Announce FDA Approval for Selarsdi with Stelara
06 May 2025 //
GLOBENEWSWIRE
Teva`s Ajovy FDA filing accepted for pediatric migraine prevention
07 Apr 2025 //
GLOBENEWSWIRE
Teva and Samsung Bioepis Launch EPYSQLI in the U.S.
07 Apr 2025 //
PRESS RELEASE
Lumicera Secures Purchase Agreement for Stelara Biosimilar
13 Mar 2025 //
BUSINESSWIRE
Teva & Sanofi present new outcome from Phase 2b study of duvakitug
25 Feb 2025 //
PRESS RELEASE
Alvotech, Teva’s BLA For AVT06 Biosimilar To Eylea Accepted By FDA
18 Feb 2025 //
GLOBENEWSWIRE
Alvotech, Teva BLA Filing Accepted For AVT05 Biosimilar To Simponi
27 Jan 2025 //
GLOBENEWSWIRE
Teva To Commercialize Formycon’s Eylea Biosimilar In Europe, Israel
13 Jan 2025 //
GLOBENEWSWIRE
Samsung Bioepis, Teva Partner For Epysqli In US
10 Jan 2025 //
GLOBENEWSWIRE
Teva, Sanofi say bowel disease drug met primary targets
18 Dec 2024 //
PRESS RELEASE
Teva Presents Positive Ph 3 Trial Data for AJOVY® in Children
04 Dec 2024 //
GLOBENEWSWIRE
Alvotech And Teva Announce FDA Approval Of SELARSDI™ Presentation
22 Oct 2024 //
GLOBENEWSWIRE
Teva brings biotech ethos to drug development, exec says
15 Oct 2024 //
FIERCE BIOTECH
Teva Prolia Biosimilar Accepted For Review By FDA And EMA
08 Oct 2024 //
GLOBENEWSWIRE
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
28 Jun 2024 //
BUSINESSWIRE
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
08 May 2024 //
REUTERS
Teva enters into oncology biosimilar licensing agreement
16 Apr 2024 //
EUROPEAN PHARMACEUTICAL REVIEW
Teva`s AJOVY® Effective, Safe For Migraine Prevention In China
11 Apr 2024 //
BUSINESSWIRE
Teva & mAbxience Announce Licensing Agreement for Oncology Biosimilar Candidate
04 Apr 2024 //
BUSINESSWIRE
Teva inks cancer biosimilar marketing pact with mAbxience
04 Apr 2024 //
FIERCE PHARMA
Teva and Alvotech`s Humira biosimilar finally snags FDA approval
24 Feb 2024 //
FIERCE PHARMA
Teva Named by Forbes as No. 1 Canadian Employer in Drugs & Biotech Industry
07 Feb 2024 //
BUSINESSWIRE
New Post Hoc Phase 3 Data Analysis Shows AJOVYReduced Migraine Attacks
06 Dec 2023 //
BUSINESSWIRE
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks
17 Oct 2023 //
BUSINESSWIRE
Teva, Alvotech ramp up biosimilar collab with 2 more products
25 Jul 2023 //
FIERCE PHARMA
Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab)
30 Jun 2023 //
BUSINESSWIRE
Teva to Present Data at the 2023 Scientific Meeting Demonstrating AJOVY
15 Jun 2023 //
BUSINESSWIRE
J&J inks Stelara biosim settlement with Alvotech and Teva
13 Jun 2023 //
FIERCE PHARMA
Teva Launches New “Pivot to Growth” Strategy
18 May 2023 //
BUSINESSWIRE
